FDA Brief

Warning letters Drugs

FDA warning letter to

AnazaoHealth Corporation

MediumIssued Aug 18, 2021Posted Aug 31, 2021Division of Pharmaceutical Quality Operations IV

AnazaoHealth Corporation compounded drugs without meeting 503B conditions, including inadequate adverse event reporting.

What happened

FDA inspected the facility from September 9 to 19, 2019, and found it failed to meet section 503B conditions because its adverse event reporting procedures were inadequate. FDA also found the company compounded unapproved new drugs and misbranded drugs. The company's responses were insufficient to fully evaluate corrective actions.

What FDA found

  1. The facility's adverse event reporting procedures did not define what an adverse event is, set reporting timelines, or require use of FDA's Safety Reporting Portal or Electronic Submission Gateway.

    section 503B(b)(5) of the FDCA [21 U.S.C. § 353b(b)(5)] and 21 CFR 211.198
  2. The company compounded new drugs without FDA-approved applications.

    sections 505(a) and 301(d) of the FDCA [21 U.S.C. §§ 355(a) and 331(d)]
  3. The company's drug products were misbranded because their labeling lacked adequate directions for use.

    section 502(f)(1) of the FDCA [21 U.S.C. § 352(f)(1)]

What FDA wants

Within 15 working days, notify FDA in writing of the specific steps taken to address the violations, including an explanation of each step and related documentation. If the company cannot completely address the matter within that time, it must state the reason for the delay and the time within which it will do so.

Who should pay attention

  • outsourcing facilities
  • compounding pharmacies
  • healthcare providers who use compounded drugs

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Naseem A. Jaffrani, M.D.

    FDA says clinical investigator Dr. Naseem Jaffrani failed to report serious adverse events to sponsors within 24 hours in two drug trials.

    High risk
  2. ProRx LLC

    ProRx LLC, an outsourcing facility, made sterile compounded drugs under insanitary conditions and without required 503B eligibility.

    High risk
  3. Apothecary Pharma, LLC

    FDA warns Apothecary Pharma, an outsourcing facility, that its sterile compounded drugs were made under insanitary conditions.

    High risk
  4. Novo Nordisk Inc.

    FDA warns Novo Nordisk over failures to report and investigate serious unexpected adverse drug experiences for drugs including semaglutide.

    High risk